Going to the 2019 Genitourinary Cancers Symposium? Make Sure to Attend Our Cleveland Clinic Sessions

Connect with our staff as we participate and present in the following sessions at the 2019 Genitourinary Cancers Symposium

Thursday, February 14:

11:30 AM-1:00 PM and 5:30 PM-6:30 PM
Poster Session A: Prostate Cancer and Trials in Progress Poster Session A: Prostate Cancer

BOARD B16
Abstract 28: The effect of the timing of biochemical failure after external beam radiotherapy or low-dose-rate brachytherapy for definitive prostate cancer treatment.
First Author: Jay Ciezki, MD

BOARD E2
Abstract 78: Moderately hypofractionated radiotherapy for localized prostate cancer: Long-term outcomes for 854 consecutive patients treated over 10 years (70 Gy in 2.5 Gy/fraction).
First Author: Omar Mian, MD, PhD

BOARD E11
Abstract 87: Prospective evaluation of a new patient decision aid to enhance prostate cancer screening decision-making.
First Author: Michael Brooks

BOARD E13
Abstract 89: Outcomes of active surveillance for African-American men with prostate cancer: Results of a matched analysis.
First Author: Lewis Thomas, M.D.

BOARD H12
Abstract 191: Determining androgen inactivation status in prostate cancer by [18F] DHT PET.
First Author: Ziqi Zhu

BOARD M12
Abstract 277: 3βHSD1 immunohistochemistry and HSD3B1 genotype in prostate cancer.
First Author: JJ Zhang, M.D.

Friday, February 15:

12:15 PM-1:45 PM and 5:15 PM-6:15 PM
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, Testicular, and Adrenal Cancers
Trials in Progress Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, Testicular, and Adrenal Cancers

BOARD C17
Abstract 135: The effect of urologic oncology fellowship training on type and yield of prostate biopsy.
First Author: Molly DeWitt-Foy, MD

BOARD J7
Abstract 436: Blood myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) are correlated with neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS).
First Author: Iris Sheng, MD

BOARD J8
Abstract 437: Correlation of myeloid-derived suppressor cells (MDSC) with pathologic complete response (pCR), recurrence free survival (RFS), and overall survival (OS) in patients with urothelial carcinoma (UC) undergoing cystectomy.
First Author: Jaleh Fallah, MD

BOARD K18
Abstract 469: Sequential intravesical gemcitabine and docetaxel in the treatment of BCG-naive patients with non-muscle invasive bladder cancer.
First Author: Lewis Thomas, M.D.

BOARD L10
Abstract 483: Plasmacytoid variant urothelial carcinoma: Clinicopathologic outcomes and experience with neoadjuvant chemotherapy.
First Author: Kyle Ericson, MD

Saturday, February 16:

7:00 AM-7:55 AM and 12:30 PM-2:00 PM
Poster Session C: Renal Cell Cancer
Trials in Progress Poster Session C: Renal Cell Cancer

BOARD D2
Abstract 541: TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
First Author: Brian Rini, MD, FACP

BOARD D19
Abstract 558: Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.
First Author: Brian Rini, MD, FACP

BOARD F4
Abstract 587: Neoadjuvant durvalumab +/- tremelimumab affects the expression of immune checkpoint (IC) molecules on myeloid derived suppressor cells (MDSC) in patients (pts) with locally advanced renal cell carcinoma (RCC).
First Author: Jaleh Fallah, MD

BOARD G9
Abstract 614: Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC).
First Author: Brian Rini, MD, FACP

7:55 AM-9:30 AM

Welcome and General Session 7: Key Questions in Localized Kidney Cancer
Risk Stratification After Resection of Localized Disease: Which Model to Use and Why
Brian I. Rini, MD
Cleveland Clinic Taussig Cancer Institute

10:00 AM-11:30 AM

General Session 8: Evolving Management of Metastatic Renal Cell Carcinoma
Abstract 541: TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
First Author: Brian I. Rini, MD, FACP